453
Views
7
CrossRef citations to date
0
Altmetric
Acne

Isotretinoin is safe and efficacious in Asians with acne vulgaris

, , , , &
Pages 387-391 | Received 12 Dec 2011, Accepted 23 Jan 2012, Published online: 12 Apr 2012
 

Abstract

Background: Oral isotretinoin is effective for acne vulgaris but concerns remain regarding its adverse effects. Objectives: This study aims to evaluate the safety and efficacy of isotretinoin for acne vulgaris in Asian patients. Methods: We conducted a 4-year retrospective study on all patients with acne vulgaris treated with isotretinoin, between January 2005 and December 2008 at the National Skin Centre in Singapore. Medical records were reviewed for information on patient demographics, acne severity, isotretinoin dose, duration, adverse effects and outcome. Results:There were 2,255 patients, with a mean age of 22.5 years, male:female ratio of 2.5:1 and 82.3% being Chinese. The mean starting dose of isotretinoin was 0.4 mg/kg and on average, patients received 7.8 months of treatment at a mean dose of 0.5 mg/kg. Mean total cumulative dose was 95.6 mg/kg. Vast majority (93.9%) achieved complete remission or substantial improvement. Thirty-eight (2.2%) and 24 patients (2.7%) developed elevated serum levels of alanine and aspartate aminotransferases subsequent to treatment. There were 194 (12.1%) and 80 (4.8%) patients who developed hyperlipidaemia and hypertriglyceridaemia respectively. Isotretinoin was generally well-tolerated, with 6.4% (n = 145) discontinuing due to side-effects. Conclusions:This study reaffirms the overall safety and efficacy of oral isotretinoin in Asian patients with acne vulgaris.

Acknowledgments

We would like to thank Cheang Qifeng, Thio Simin and Veron Lu for their help in this study.

Declaration of interest: Douglas Pharmaceuticals Limited funded manpower support to facilitate data extraction. The company did not have any influence on the study design, data collection and analysis, study outcome, results, manuscript preparation and revision.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.